-
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
-- Exceptional Approval is Based on Data from Global Clinical Trials and Gilead’s Compassionate Use Program -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) ...
-
-- Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19 Patients Receiving Standard ...
-
-- Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States -- -- Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients -- ...
-
– Double-Blind Placebo-Controlled Study Evaluated the Efficacy of Early Use of Veklury IV in Non-Hospitalized Patients – – Late-breaking Data to be Presented at IDWeek 2021 – ...
-
-- Veklury is Now Recommended by the WHO for Use in Both Non-Severe COVID-19 Patients at the Highest Risk of Hospitalization and Patients with Severe COVID-19 -- FOSTER CITY, Calif.--(BUSINESS ...
-
-- Real-World Evidence from More than 850,000 Hospitalized Patients Provides Clinical Insights on the Use of Veklury (Remdesivir) as Standard-of-Care COVID-19 Treatment -- -- New ...
-
– Veklury Was Associated With a Lower Risk of Developing Long-COVID in One Analysis – – Veklury Was Associated With a Reduced Risk of Mortality Among People Who Are Immunocompromised in a Separate ...
-
-- If Granted by the European Commission, Veklury Will Become the First and Only Authorized Antiviral Treatment for Pediatric Patients Under 12 Years of Age in the European Union -- FOSTER ...
-
-- Veklury is the First Approved Treatment Option for COVID-19 in the European Union -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European ...
-
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
-- Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone -- -- Data Add to Body ...